VANCOUVER, British Columbia -- Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company’s diagnostic products, expanding its strategic presence in this important global market.
“We have already seen great success in China with our first partner, O&D Biotech Co., Ltd. China (O&D), selling our co-branded RAMP® cardiac products over the past few years,�said S. Wayne Kay, Chief Executive Officer. “In 2009, we recognized a significant portion of our revenues from sales in China. We are pleased to sign the Wondfo agreement and with representation by two strong partners in this region, we expect sales in China to continue to make an important contribution to our overall revenues.�
fake rolex "China is an exciting and growing market and our continued international market expansion is extremely important to our overall strategy. Wondfo will be selling private label cardiac products, while O&D sells co-branded RAMP® products on both the RAMP® and RAMP® 200 Readers."
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
The RAMP® system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, influenza and RSV through our commercial partners, Roche and 3M Health Care respectively and the Company.
In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development.
Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.
Human hair wigs Response Biomedical is a publicly-traded company listed on the TSX under the trading symbol "RBM"Â and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at .
Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", “goal�and similar expressions, are "forward-looking statements" or “forward-looking information�under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and th
Other articles:
http://boling881100.bokee.com/viewdiary.46611056.html
